Physician profile
Katelyn Totten
NPI 1497318935
$1,156.13
in general payments reported to CMS, 2019-2025
11 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Surgical provider received nationally (typical 2025 total: $146).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $336 · 2022: $88.47 · 2023: $368 · 2024: $163 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $329.85 | 2022-2025 | Variax, T2 Alpha, Biolox |
| Pacira Pharmaceuticals Incorporated | $203.59 | 2021-2024 | Exparel, Zilretta, Iovera |
| Bioventus LLC | $167.93 | 2021-2025 | Exogen Ultrasound Bone Healing System |
| Abbvie INC. | $132.00 | 2021 | |
| Zimvie INC. | $127.15 | 2023 | |
| Kci USA, INC. | $71.43 | 2023 | Prevena, V.A.C. Veraflo |
| Solventum Corporation | $46.93 | 2025 | V.A.C.Instill, Prevena, V.A.C.Ulta |
| Smith+Nephew, INC. | $22.33 | 2022 | |
| Medacta USA, INC. | $21.99 | 2024 | |
| Vertex Pharmaceuticals Incorporated | $17.28 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $15.65 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katelyn Totten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.